Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
- CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM , June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation in the BIO International Convention 2025 (June 16–19, Boston).
- 06/12/2025
|
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
- Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors.
- 06/04/2025
|
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
- JERUSALEM , May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025.
- 05/30/2025
|
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
- First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
- 05/21/2025
|
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI
- BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in the development of plant-derived biological materials for use in approved drugs.
- 05/17/2025
|
BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stage
- BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product.
- 05/12/2025
|
BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
- Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product.
- 05/12/2025
|
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
- CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference.
- 04/22/2025
|
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
- SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.
- 03/23/2025
|
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
- Humanetics' Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM)
- 03/17/2025
|
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
- JERUSALEM , March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be meeting with investors, showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO boutique services at the BIO-Europe Spring 2025 conference, taking place March 17-19 in Milan, Italy.
- 03/17/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/24/2025
|
An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/23/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/22/2025
|
An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/21/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/20/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/19/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/18/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/17/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/16/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/15/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/14/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/13/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/11/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/10/2025
|
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
- TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers.
- 02/10/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/09/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/08/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/07/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/06/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/05/2025
|
Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger
- TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the “Notice”) to holders of its 7.00% Convertible Senior Notes due 2029 (the “Notes”), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the “Indenture”), by and between the Company and U.S. Bank Trust Company, National Association (“U.S. Bank”), as trustee, governing the Notes that, in connection with the closing of the transaction contemplated by the Agreement and Plan of Merger, dated as of November 6, 2024 (the “Merger Agreement” and such transaction, the “Merger”), by and among Avid, Space Finco, Inc. and Space Mergerco, Inc., a Fundamental Change and a Make-Whole Fundamental Change (each as defined in the Indenture) occurred under the Indenture on February 5, 2025.
- 02/05/2025
|
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
- Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
- 02/05/2025
|
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
- LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampersand”), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices (“Avid” of the “Company”), a dedicated biologics Contract Development and Manufacturing Organisation (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies.
- 02/05/2025
|
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
- LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/03/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/02/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 02/01/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/31/2025
|
Avid Stockholders Approve Transaction with GHO and Ampersand
- TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) at the Avid special meeting of stockholders (the “Special Meeting”) held earlier today.
- 01/30/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/30/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/28/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/27/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/26/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/25/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/24/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/23/2025
|
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
- Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders
- 01/22/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/22/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/21/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/20/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/19/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/18/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/17/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/16/2025
|
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/15/2025
|
Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Shareholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 01/15/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/14/2025
|
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/13/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/12/2025
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avid Bioservices, Inc. (CDMO) And Encourages Shareholders to Connect
- NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 01/12/2025
|
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/10/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/09/2025
|
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
- TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) on its investor relations website.
- 01/08/2025
|
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/08/2025
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avid Bioservices, Inc. (CDMO) And Encourages Shareholders to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 01/08/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/07/2025
|
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices, Inc. (NasdaqCM: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners. Under the terms of the proposed transaction, shareholders of Avid will receive $12.50 in cash for each share of Avid that they own. KSF is seeking to determine whether this consideration and the.
- 01/06/2025
|
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/06/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/05/2025
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Shareholders to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 01/05/2025
|
Avid Bioservices Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/04/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/03/2025
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / January 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 01/02/2025
|
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/31/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/30/2024
|
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
- TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced agreement for Avid to be acquired by GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”).
- 12/30/2024
|
The Schall Law Firm Invites Shareholders To Take Part In An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/29/2024
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avid Bioservices, Inc. (CDMO) And Encourages Investors to Connect
- NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/29/2024
|
CDMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avid Bioservices, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners for $12.50 per share in cash is fair to Avid shareholders. Halper Sadeh encourages Avid shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.
- 12/28/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/28/2024
|
The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/27/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/26/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Stockholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/26/2024
|
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/24/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/23/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Investors to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/22/2024
|
The Schall Law Firm Urges Stockholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/21/2024
|
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/20/2024
|
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc. For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/19/2024
|
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
- Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
- 12/19/2024
|
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
- TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has commenced mailing definitive proxy materials and a letter to stockholders in connection with its pending transaction with GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”).
- 12/18/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/18/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avid Bioservices, Inc. (CDMO) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/18/2024
|
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/17/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/16/2024
|
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
- JERUSALEM , Dec. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today the establishment of a U.S.-based subsidiary for its Contract Development and Manufacturing Services.
- 12/16/2024
|
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/15/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Investors to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/15/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/14/2024
|
The Schall Law Firm Urges Stockholder Participation In An Inquiry Into Avid Bioservices Inc For Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/13/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Related Infractions And Affected Investors Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/12/2024
|
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Avid Bioservices Inc For Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/11/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avid Bioservices, Inc. (CDMO) And Encourages Investors to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/11/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/10/2024
|
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
- TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024.
- 12/10/2024
|
The Schall Law Firm Encourages Stockholder Contributions To An Inquiry Into Avid Bioservices Inc's Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/09/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/08/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avid Bioservices, Inc. (CDMO) And Encourages Stockholders to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / December 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/08/2024
|
The Schall Law Firm Urges Public Participation In An Inquiry Into Avid Bioservices Inc's Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/07/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Assist The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/06/2024
|
The Schall Law Firm Urges Stockholders To Take Part In An Inquiry Into Avid Bioservices Inc's Possible Securities Fraud
- LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/05/2024
|
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
- 12/05/2024
|
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Reach Out To The Schall Law Firm
- LOS ANGELES, CA / ACCESSWIRE / December 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
- 12/04/2024
|
CDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--CDMO Investors Have the Opportunity to Join Investigation of Avid Bioservices, Inc. with the Schall Law Firm.
- 12/02/2024
|
Lifecore Biomedical: An Interesting CDMO Pure Play
- Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production capacity, enhancing financial performance, and attracting new customers with advanced technology and strategic investments. Despite a challenging Q1, Lifecore anticipates significant revenue growth and improved EBITDA in H2 FY25, driven by increased capacity utilization and cost management.
- 12/01/2024
|
Punch and Associates sends letter to Board of Directors of Avid Bioservices, Inc.
- MINNEAPOLIS--(BUSINESS WIRE)--Punch & Associates intends to vote AGAINST proposed acquisition of Avid Bioservices, Inc. by GHO Capital and Ampersand Capital.
- 11/14/2024
|
Semi-Solid Dosage CDMO Market Report 2024-2030: The Lubrizol Corporation, Cambrex Corporation, and Contract Pharmaceuticals Dominate the Competitive Landscape
- Dublin, Nov. 13, 2024 (GLOBE NEWSWIRE) -- The "Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis by Route of Administration (Topical, Transdermal, Others), Product, Service, End-use, and Country, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global semi-solid Dosage CDMO market is expected to reach USD 67.4 billion by 2030, and anticipated to grow at a CAGR of 11.80% from 2024 to 2030.
- 11/13/2024
|
AVID BIOSERVICES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avid Bioservices, Inc. - CDMO
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices, Inc. (NasdaqCM: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners. Under the terms of the proposed transaction, shareholders of Avid will receive $12.50 in cash for each share of Avid that they own. KSF is seeking to determine whether this consideration and the.
- 11/09/2024
|
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Avid Bioservices, Inc. – CDMO
- NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Avid Bioservices, Inc. (NASDAQ: CDMO ), relating to its proposed acquisition by GHO Capital Partners and Ampersand Capital Partners. Under the terms of the agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid's stockholders for $12.50 per share in cash.
- 11/08/2024
|
Shareholder Alert: Ademi LLP Investigates Whether Avid Bioservices, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, stockholders of Avid will receive only $12.50 per share in an all-cash transaction valued at approximatel.
- 11/08/2024
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avid Bioservices, Inc.
- NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. (NASDAQ: CDMO) and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP and Ampersand Capital Partners. Stockholders will receive $12.50 for each share of Avid Bioservices stock that they hold.
- 11/07/2024
|
CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners
- MONSEY, New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Avid Bioservices (Nasdaq: CDMO) (“Avid”) to GHO Capital Partners (“GHO”) and Ampersand Capital Partners (“Ampersand”) for $12.50 per share in cash. The sale price is below the price target for Avid of $14.00 per share of Wall Street analyst Paul Knight of KeyBanc (source: TipRanks).
- 11/07/2024
|
Avid Bioservices to be acquired by GHO and Ampersand for about $1.1 bln
- Avid Bioservices said on Wednesday that it has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion.
- 11/06/2024
|
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
- TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) today announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion.
- 11/06/2024
|
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
- JERUSALEM , Oct. 31, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.
- 10/31/2024
|
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
- Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
- 09/18/2024
|
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
- TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, and Pramthesh Patel, Ph.D., vice president of process development, will be the featured speakers in a fireside chat at the conference, which will take place virtually on September 19, 2024.
- 09/12/2024
|
Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2025 Earnings Conference Call September 9, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Group Paul Knight - KeyBanc Capital Markets Max Smock - William Blair Operator Good day and thank you for standing by. Welcome to the Avid Bioservices First Quarter Fiscal Year 2025 Financial Results Conference Call.
- 09/09/2024
|
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
- -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million --
- 09/09/2024
|
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
- TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
- 09/03/2024
|
Lifecore Biomedical Announces Chief Financial Officer Transition
- Experienced CDMO Industry Financial Executive Ryan Lake Appointed CFO Experienced CDMO Industry Financial Executive Ryan Lake Appointed CFO
- 08/29/2024
|
Avid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2024 Earnings Conference Call July 2, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President & CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Jacob Johnson - Stephens Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Max Smock - William Blair Operator Thank you for standing by, and welcome to the Avid Bioservices Fourth Quarter Fiscal Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 07/02/2024
|
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
- -- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million --
- 07/02/2024
|
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
- TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and fiscal year ended April 30, 2024, and review recent corporate developments.
- 07/01/2024
|
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
- Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. Priothera is headquartered in Dublin, Ireland, and has a subsidiary in Saint-Louis (Haut-Rhin), France.
- 06/18/2024
|
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
- TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has achieved a Committed Badge from EcoVadis, one of the world's most trusted providers of business sustainability ratings. Avid earned a score of 56 from EcoVadis, placing the company in the 62nd percentile globally.
- 05/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
- NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/16/2024
|
Avid Bioservices: A Unique Growth Story With Many Tailwinds And Catalysts
- Although Avid is 30+ years old, the story has become much more exciting due to the shift to a pure-play biologics CDMO, pharma increasingly outsourcing biologics, and record revenue-generating capacity. Avid has an economic moat with its mission-critical, leading role in specialty manufacturing, the long-term stability and predictability in its cash flows, and high barriers to entry & exit. I present many potential catalysts, such as CTLT's sale to Novo, the BIOSECURE Act, commercialization of former assets, improved funding conditions, and a potential take-private.
- 05/16/2024
|
Avid Bioservices to Participate at Upcoming Investor Conferences
- TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming investor conferences. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference, and will deliver a corporate presentation at the 2024 Bank of America Securities Healthcare Conference.
- 05/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
- NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/06/2024
|
Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q3 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Tim Brons – Investors Relations Group Nick Green – President and Chief Executive Officer Dan Hart – Chief Financial Officer Matt Kwietniak – Chief Commercial Officer Conference Call Participants Jacob Johnson – Stephens Sean Dodge – RBC Capital Markets Matt Hewitt – Craig-Hallum Capital Group Max Smock – William Blair Paul Knight – KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Avid Bioservices Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 04/29/2024
|
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
- -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million --
- 04/24/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
- NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/12/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
- NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 04/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
- NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avid Bioservices, Inc. ("Avid" or the "Company") (NASDAQ: CDMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 03/27/2024
|
Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape – ResearchAndMarkets.com
- DUBLIN–(BUSINESS WIRE)–The “Global Contract Development and Manufacturing Organization Market: Analysis By Type, By Product, By Sourcing, By Application, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029” report has been added to ResearchAndMarkets.com’s offering. The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, … The post Global Contract Development and Manufacturing Organization Market Analysis Report...
- 03/22/2024
|
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
- TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 (the “Form 10-Q”) in a timely manner.
- 03/20/2024
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Avid investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.
- 03/14/2024
|
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK--(BUSINESS WIRE)---- $CDMO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO). Investors who purchased Avid Bioservices securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO. Investigation Details: On March 6, 2024, Avid Bioservices filed a current report on Form 8-K with.
- 03/14/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) investors concerning the Company's possible violations of federal securities laws. On March 6, 2024, Avid disclosed that it had received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026. The holder further claimed that the accelerated amount, inclusive of principal and interest due and payable,.
- 03/13/2024
|
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 6, 2024, Avid disclosed that it had received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026. The holder further claimed that.
- 03/13/2024
|
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
- NEW YORK--(BUSINESS WIRE)---- $CDMO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avid Bioservices, Inc. (“Avid Bioservices” or “the Company”) (NASDAQ: CDMO). Investors who purchased Avid Bioservices securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO. Investigation Details: On March 6, 2024, Avid Bioservices filed a current report on Form 8-K with.
- 03/07/2024
|
CDMO LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Avid Bioservices, Inc. (NASDAQ: CDMO) resulting from allegations that Avid Bioservices may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Avid Bioservices securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting.
- 03/07/2024
|
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
- Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
- 03/07/2024
|
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
- TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is subject to customary closing conditions and is expected to take place on March 12, 2024.
- 03/06/2024
|
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
- TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The company expects to price the Offering before open of market on March 7, 2024.
- 03/06/2024
|
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
- TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.
- 03/06/2024
|
Avid Bioservices: Don't Miss The Bigger Picture
- Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.
- 01/07/2024
|
Why Is Avid Bioservices (CDMO) Stock Down 18% Today?
- Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
- 12/08/2023
|
CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Revenue for Q2 2024
- Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
- 12/07/2023
|
Avid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q2 2024 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Tim Brons - Investors Relations Group Nick Green - President and CEO Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Max Smock - William Blair Thomas Kelliher - RBC Capital Markets Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2024 Financial Results Conference Call.
- 12/07/2023
|
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
- Avid Bioservices (CDMO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.01 per share a year ago.
- 12/07/2023
|
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
- TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
- 11/30/2023
|
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
- Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 11/28/2023
|
From laggards to leaders: Small caps on the rise
- Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, but also Royal Caribbean Cruises Ltd. NYSE: RCL and PulteGroup Inc. NYSE: PHM.
- 11/27/2023
|
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
- Avid Bioservices (CDMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 11/15/2023
|
Avid Bioservices, Inc. (CDMO) Q1 2024 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2024 Earnings Conference Call September 7, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President & Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Sean Dodge - RBC Capital Markets Operator Good day, ladies and gentlemen and welcome to the Avid Bioservices First Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded.
- 09/07/2023
|
Avid Bioservices (CDMO) Reports Break-Even Earnings for Q1
- Avid Bioservices (CDMO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
- 09/07/2023
|
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
- TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2024 on September 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
- 08/31/2023
|
Why Avid Bioservices Stock Was Plummeting This Week
- Investors did not warmly greet the latest earnings report from the contract pharmaceutical manufacturer and developer. The company flipped into the red on the bottom line, and proffered uninspiring revenue guidance.
- 06/23/2023
|
Why Shares of Avid Bioservices Are Dropping Thursday
- Avid grew revenue in the quarter and in the year. The company reported falling earnings per share in both the quarter and the year.
- 06/22/2023
|
Avid Bioservices, Inc. (CDMO) Q4 2023 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2023 Earnings Conference Call June 21, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and CEO Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Capital Jacob Johnson - Stephens Thomas Kelliher - RBC Capital Market Operator Good day, ladies, and gentlemen, and welcome to the Avid Bioservices Fourth Quarter and Year-End Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 06/21/2023
|
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023
- TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2023 on June 21, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and fiscal year ended April 30, 2023, and review recent corporate developments.
- 06/14/2023
|
Avid Bioservices Bolsters Manufacturing Capabilities And Generates High-Demand Services
- Avid Bioservices has recently completed two expansions within its mammalian cell facilities, increasing its manufacturing capacity and potential revenue generating capacity. The company is involved in several products at different stages of development, including a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency.
- 05/20/2023
|
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, biologics, and novel proteins for biotech, healthcare, and pharmaceutical companies. Monoclonal antibodies were a hot topic of discussion during the pandemic.
- 03/14/2023
|
Why Avid Bioservices Stock Is Surging Today
- Avid Bioservices' fiscal 2023 third-quarter earnings report painted an encouraging picture. Even so, the biotech's stock may be close to fair value after today's double-digit move higher.
- 03/14/2023
|
CDMO Stock: 10.85% Increase After Hours Explanation
- The stock price of Avid Bioservices Inc (NASDAQ: CDMO) increased by 10.85% after hours in the most recent trading session. This is why.
- 03/13/2023
|
Avid Bioservices, Inc. (CDMO) Q3 2023 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q3 2023 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Jacob Johnson - Stephens Paul Knight - KeyBanc Operator Good day, ladies and gentlemen and welcome to the Avid Bioservices Third Quarter Fiscal 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded.
- 03/13/2023
|
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 275% and 5.61%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
- 03/13/2023
|
Steer Clear Of These 4 Toxic Stocks to Avoid Losses
- Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.
- 03/10/2023
|
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023
- TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2023 on March 13, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.
- 03/06/2023
|
Avid Bioservices: Production Expansion Capex And High Costs Are Temporary Issues
- Avid Bioservices is a CDMO, or a company that manufactures therapies for biotechs and pharmaceuticals. To grow revenues, the company is investing heavily in expanding their production, hurting cash flows in the process.
- 12/09/2022
|
Avid Bioservices, Inc. (CDMO) Q2 2023 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q2 2023 Results Conference Call December 6, 2022 4:30 PM ET Company Participants Tim Brons - IR Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Paul Knight - KeyBanc Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2023 Financial Results Conference Call.
- 12/06/2022
|
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
- 12/06/2022
|
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
- TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
- 11/29/2022
|
Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?
- The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 10/17/2022
|
Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
- TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.
- 09/07/2022
|
Avid Bioservices, Inc. (CDMO) Q1 2023 Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2023 Earnings Conference Call September 6, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Thomas Kelliher - RBC Capital Markets Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Operator Good day, ladies and gentlemen. Welcome to the Avid Bioservices First Quarter Fiscal 2023 Financial Results Conference Call.
- 09/06/2022
|
Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
- 09/06/2022
|
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
- TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
- 08/30/2022
|
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2022 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2022 Earnings Conference Call June 29, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Capital Operator Good day ladies and gentlemen and welcome to the Avid Bioservices Fourth Quarter and Fiscal Year End 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded.
- 06/29/2022
|
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
- TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2022 and review recent corporate developments.
- 06/22/2022
|
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
- Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
- 05/11/2022
|
Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript
- Avid Bioservices' (CDMO) CEO Nick Green on Q3 2022 Results - Earnings Call Transcript
- 03/08/2022
|
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2022
|
Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know
- Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.
- 02/01/2022
|
Avid Bioservices Expands Production Capacity To Continue Growth Trajectory
- One unduly sold-off company of late is Avid Bioservices, with only positive news of late guiding to performance beyond expectations.
- 01/29/2022
|
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
- 3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
- 12/29/2021
|
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
- Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.
- 12/21/2021
|
Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 12/15/2021
|
Avid Bioservices (CDMO) Tops Q2 Earnings and Revenue Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 400% and 4.44%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
- 12/08/2021
|
Avid Bioservices, Inc.'s (CDMO) CEO Nick Green on Q2 2022 Results - Earnings Call Transcript
- Avid Bioservices, Inc.'s (CDMO) CEO Nick Green on Q2 2022 Results - Earnings Call Transcript
- 12/07/2021
|
Avid Bioservices: Q2 Earnings Insights
- Avid Bioservices (NASDAQ:CDMO) reported its Q2 earnings results on Tuesday, December 7, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
- 12/07/2021
|
Earnings Preview: Avid Bioservices
- Avid Bioservices (NASDAQ:CDMO) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.
- 12/06/2021
|
7 A-Rated Biotechs to Buy for the Long Run
- The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
- 12/03/2021
|
Avid Bioservices (CDMO) Earnings Expected to Grow: What to Know Ahead of Q2 Release
- Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/24/2021
|
Will The Rally In Avid Bioservices Stock Continue After 48% Rise In A Month?
- The stock price of Avid Bioservices, a contract development and manufacturing company for biopharmaceutical products, has surged 48% in a month (twenty-one trading days), while it is up a solid 19% in a week. The recent rise can be attributed to CDMO's inclusion in the S&P SmallCap 600 index.
- 11/01/2021
|
Why Avid Bioservices Stock Surged 14% Today
- The stock will be part of a well-known index.
- 10/26/2021
|
Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks' Debut on Sept. 17
- Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.
- 09/15/2021
|
Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
- Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 09/14/2021
|
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
- 09/08/2021
|
Avid Bioservices: FDA CGMP Stringency Provides Stable Long Outlook
- Healthcare is one market no one can say is going to slow down, and so, many of the best investments lie within.
- 08/11/2021
|
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D.
- Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience
- 07/01/2021
|
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript
- 06/29/2021
|
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
- -- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --
- 06/29/2021
|
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
- TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2021 and review recent corporate developments.
- 06/22/2021
|
Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?
- Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 06/22/2021
|
7 A-Rated Biotech Stocks to Buy Now
- Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 06/15/2021
|
Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?
- Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/04/2021
|
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
- Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.
- 05/12/2021
|
5 Stocks to Buy on New Analyst Coverage
- Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
- 04/07/2021
|
Find Strong Stocks to Start Q2 with New Analyst Coverage
- Find Strong Stocks to Start Q2 with New Analyst Coverage
- 04/07/2021
|
Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).
- 04/06/2021
|
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
- Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon
- 03/12/2021
|
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q3 2021 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q3 2021 Results - Earnings Call Transcript
- 03/08/2021
|
Avid Bioservices (CDMO) Surpasses Q3 Earnings and Revenue Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 150.00% and 9.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2021
|
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
- TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Avid SPV, LLC (the “Issuer”), intends to sell, subject to market and other conditions, $125 million aggregate principal amount of exchangeable senior notes due 2026 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Issuer also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $18.75 million aggregate principal amount of the notes.
- 03/08/2021
|
Avid Bioservices: Q3 Earnings Insights
- Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 116.67% over the past year to $0.01, which beat the estimate of ($0.03).
- 03/08/2021
|
7 Biotech Stocks Focused on Chronic Covid Treatment
- Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
- 02/22/2021
|
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
- Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites
- 02/22/2021
|
Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
- BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen's therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune h
- 02/03/2021
|
Avid Bioservices Announces Closing of Public Offering of Common Stock
- TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the closing of its previously announced underwritten public offering of 3,833,335 shares of its common stock, including 500,000 shares sold pursuant to the underwriters' exercise of their option to purchase additional shares. The offering price was $9.00 per share, and the gross proceeds from the offering were approximately $34.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. Avid Bioservices, Inc. intends to use the net proceeds from the offering primarily for the expansion of its manufacturing capabilities and any remainder for general corporate purposes.
- 12/14/2020
|
Avid Bioservices Announces Pricing of Public Offering of Common Stock
- TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the pricing of an underwritten public offering of 3,333,335 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Avid Bioservices, Inc. The offering is expected to close on or about December 14, 2020, subject to customary closing conditions. Avid Bioservices, Inc. has also granted the underwriters a 30-day option to purchase from it up to an additional 500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Avid Bioservices, Inc. intends to use the net proceeds from the offering primarily for the expansion of its manufacturing capabilities and any remainder for general corporate purposes.
- 12/10/2020
|
Avid Bioservices Announces Proposed Public Offering of Common Stock
- TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has commenced an underwritten public offering of its common stock. Avid Bioservices, Inc. also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering. Avid Bioservices, Inc. intends to use the net proceeds from the offering primarily for the expansion of its manufacturing capabilities and any remainder for general corporate purposes.
- 12/09/2020
|
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
- TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company's board of directors. Ms. Thoma is a seasoned pharmaceutical industry executive with more than 30 years of experience spanning product development and commercialization, as well as operations and supply chain management.
- 12/07/2020
|
Why Avid Bioservices Stock Is Soaring Today
- The company reported great fiscal 2021 Q2 results.
- 12/03/2020
|
Avid Bioservices' (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
- Avid Bioservices' (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
- 12/02/2020
|
Recap: Avid Bioservices Q2 Earnings
- Shares of Avid Bioservices (NASDAQ:CDMO) moved higher by 8.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 133.33% over the past year to $0.01, which beat the estimate of ($0.06).
- 12/02/2020
|
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments
- -- Recorded Second Quarter Revenue of $ 21 .1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million --
- 12/02/2020
|
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
- TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
- 12/01/2020
|
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2021 Earnings Conference Call September 01, 2020 04:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and CEO Dan Hart - Chief Financial Officer Timothy Compton - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Jacob Johnson - Stephens Presentation Operator Good day, ladies and gentlemen, and welcome to the Avid Bioservices First Quarter Fiscal 2021 Financial Results Conference Call.
- 09/01/2020
|
Laughing Water Capital is Betting on Avid Bioservices (CDMO) Stock
- Laughing Water Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 29.5% for the quarter (net of fees), outperforming their benchmark, the S&P 500 Index which returned 20.5% in the same quarter. You should check out Laughing Water Capital's top 5 stock […]
- 08/19/2020
|
Avid Bioservices, Inc. (NASDAQ:CDMO): Is Breakeven Near?
- Avid Bioservices, Inc.'s (NASDAQ:CDMO): Avid Bioservices, Inc., a contract development and manufacturing organization...
- 08/10/2020
|
When Will Avid Bioservices, Inc. (NASDAQ:CDMO) Breakeven?
- Avid Bioservices, Inc.'s (NASDAQ:CDMO): Avid Bioservices, Inc., a contract development and manufacturing organization...
- 08/10/2020
|
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
- TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein. Cell line development activities for IOV-3001 are currently being conducted by Aragen Bioscience under a subcontracting agreement with Avid. In parallel with cell line development, Avid will commence analytical activities, upstream and downstream process development, and pilot-scale non-GMP manufacturing for IOV-3001. Following completion of these activities, Avid will advance to CGMP manufacturing of IOV-3001 within Avid’s state-of-the-art Myford facility in Tustin, CA.“We are pleased to be selected by Iovance to provide CDMO services to support the company’s continued advancement in developing novel anti-cancer drug candidates. As an Interleukin-2/antibody engrafted protein, IOV-3001 is the type of complex therapeutic candidate for which Avid possesses unique process development and manufacturing expertise, illustrated by our 27 years of producing related compounds,” said Timothy Compton, chief commercial officer of Avid. “This new contract award also illustrates the value of Avid’s efforts to establish alliances with key providers of complementary CDMO services such as Aragen. We are pleased to have them contribute their cell line development expertise to this project.”About Avid Bioservices, Inc.Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 27 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com
- 08/06/2020
|
Laughing Water Capital H1 2020 Letter
- Laughing Water Capital is a concentrated, long-biased investment partnership open to accredited investors.
- 07/28/2020
|
Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing
- Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic TherapeuticsTUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, and Argonaut Manufacturing Services, a CGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies, today announced a co-marketing agreement that will provide clients an integrated manufacturing solution including process development, drug substance manufacturing, and drug product manufacturing. Under terms of the non-exclusive agreement, the companies will offer Avid’s upstream and downstream process development and drug substance manufacturing services in tandem with Argonaut’s parenteral drug product fill-finish services, to support the efficient delivery of CGMP parenteral drug products for use in clinical studies. “As we continue to expand our biologics manufacturing client base, Avid is leveraging a strategy of aligning with industry leaders that are capable of offering critical complementary services to our customers,” said Timothy Compton, chief commercial officer of Avid. “In entering this agreement with Argonaut, we are offering our clients access to CGMP qualified parenteral fill-finish services within an hour’s drive from our drug substance development and manufacturing facilities. This will provide a drug substance-to-drug product solution for our clients as they move their novel, high-value biologic therapeutics through clinical development. Avid will be well positioned to support Argonaut customers that require downstream and upstream process development, as well as clinical and commercial CGMP drug substance manufacturing services, by delivering on our deep CDMO expertise and more than 15 years of commercial manufacturing experience.”“Argonaut has always endeavored to provide our clients with a trusted network of complementary service providers through our Ecosystem Partnership program,” said Eric Blair, chief commercial officer of Argonaut. “Our partnership with Avid unlocks key process development and drug substance manufacturing capabilities for our clients, which are a perfect fit with our state-of-the-art aseptic fill-finish offering. Together, Avid and Argonaut offer a complete solution for customers that are bringing biologic therapeutics to market.”About Avid Bioservices, Inc. Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 27 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs, the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.comAbout Argonaut Manufacturing ServicesArgonaut Manufacturing Services is an FDA registered, ISO 13485:2016 cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies. Life sciences and molecular diagnostics services include formulation, filling, lyophilization, and kitting, while biopharmaceutical services feature state-of-the-art automated aseptic fill-finish equipment for sterile injectable drugs. All projects are supported by a full analytical quality control service offering and global shipping logistics. From procurement through pick-pack-ship, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. www.argonautms.com CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com Eric Blair Argonaut Manufacturing Services 760-224-0844 eric@argonautms.com
- 07/28/2020
|
Is Avid Bioservices, Inc. (CDMO) Going to Burn These Hedge Funds?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 07/05/2020
|
How Much Of Avid Bioservices, Inc. (NASDAQ:CDMO) Do Insiders Own?
- The big shareholder groups in Avid Bioservices, Inc. (NASDAQ:CDMO) have power over the company. Insiders often own a...
- 07/03/2020
|
Avid Bioservices (NASDAQ:CDMO) Upgraded to “Buy” by BidaskClub
- Avid Bioservices (NASDAQ:CDMO) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, BidAskClub reports. Several other brokerages have also recently commented on CDMO. Zacks Investment Research cut shares of Avid Bioservices from a “buy” rating to a “hold” […]
- 07/03/2020
|
Analysts Say These 3 Stocks Are Their Top Picks for Post-Pandemic Gains
- Amid the market’s wild roller coaster ride, one fact has become abundantly clear: COVID-19 is a game-changer. With the number of new cases spiking, the resumption of normality is fading farther off into the distance, taking hopes of a V-shaped recovery along with it. That said, regardless of the recovery’s shape, some argue that the investing landscape has been altered for the foreseeable future.Against this backdrop, investment strategies will need to take the new reality into consideration, focusing on the names poised to emerge from the crisis as the ultimate winners. Even though this might feel like guesswork, the Street’s pros can help steer investors in the right direction.To this end, we used TipRanks’ database to get all the details on three Buy-rated stocks flagged by analysts as positioned for gains in a post-COVID environment.Adtran Inc. (ADTN)As one of the top providers of networking and communications equipment, Adtran helps communications services companies manage and scale services that connect people from all over the world. With COVID-19 making residential broadband access a necessity, some analysts see this name as a key beneficiary of the global pandemic.MKM Partners’ Michael Genovese reminds investors that during the firm’s virtual idea dinner on March 14, he laid out the case for ADTN, with COVID-19's impact only supporting his belief that the stock is a top pick. “In our view, the Adtran story has gotten even better post COVID-19 since home Broadband has gone up in importance. We believe Internet 3.0, with a good portion of human work and social life occurring online, is here to stay. We see a renewed Telco focus on Wireline and on the Edge of the network where Adtran plays,” he commented.When it comes to its Fiber products, the last few years have seen the company place a significant focus on this aspect of the business, with it revamping its PON capabilities and offering Fiber platforms with innovative SDN and Cloud features.According to Genovese, these efforts have already paid off. “Over the past year, Adtran has successfully transitioned its largest copper customers, CenturyLink and DT (DTE), into large fiber customers. Adtran's 1Q20 its Fiber revenues were up 26% year-over-year. Last month, ADTN announced a win with DT to add significantly more Fiber over the next several years,” the analyst stated.Adding to the good news, the company revealed BT Openreach had chosen it to help it make multi-gigabit services available to 20 million homes in the UK. It should be noted that in the UK, Huawei equipment can only account for 35% of the Broadband Access network. As Genovese points out, to limit its use of Huawei products, BT has turned to other providers like ADTN.“According to our checks, Adtran could see more than $10 million in sales from BT Openreach in 2Q20. We believe the contract with BT is long-term and worth hundreds of millions of dollars over time. Adtran also recently revealed a Fiber win with a U.S. Tier 1 we think it is Verizon, with revenues expected to ramp in 2021,” Genovese explained.Given the fact that the Tier 3 market is stronger than it has ever been and that the stock is trading at an attractive level, the deal is sealed for Genovese. As a result, the four-star analyst maintained a Buy rating and $16 price target. This figure puts the upside potential at 50%. (To watch Genovese’s track record, click here)Turning now to the rest of the Street, opinions are split almost evenly. 3 Buys and 2 Holds add up to a Moderate Buy consensus rating. At $14, the average price target brings the upside potential to 30%. (See Adtran stock analysis on TipRanks)Sirius XM Holdings (SIRI)Next up we have Sirius XM Holdings, a leading audio entertainment company that offers a platform for subscription and digital advertising-supported audio products. While shares have underperformed the broader market since February 19, several factors could help SIRI take off post-pandemic.Citing recent comments from CFO David Frear as well as an improved outlook for new car sales in the U.S., J.P. Morgan analyst Sebastiano Petti sees SIRI’s long-term growth prospects as being even stronger. “We are increasingly bullish on the fundamentals of the legacy SIRI business as auto sales improve from April’s trough and churn/conversion rates come in better than initially expected exiting 1Q,” he explained. The above also supported the firm’s decision to make it the top pick in June’s Spectrum of Opportunity report.Looking at the company’s standing, Petti likes its “resilient subscription business model, strong FCF generation, low leverage, solid liquidity profile, and an improving backdrop.” He also stated, “At 14.6x 2021E FCF (16.6x fully-taxed), we believe SIRI shares are attractively valued given the company’s strong growth outlook as trends normalize post-COVID-19.”All of the above prompted Petti to bump up his estimate for EBITDA by 3%, with the figure now landing at $603 million. On top of this, the analyst also trimmed his call for 2020 SIRI self-pay net losses to 925,000, from the previous estimate of -1.11 million. What drove this revision? Better-than-expected new and used auto sales in the second quarter.“We see potential upside to our 2020 self-pay net add estimate given the likelihood for 2020 SAAR over 12.5 million following May’s better than expected results, continued dealership re-openings, and pickup in economic activity. In mid-May, SIRI’s CFO noted that new car sales were 35% below the prior year with used car sales trending ~20% lower year-over-year – better than declines of 55-60% at the time of 1Q earnings. Consistent with management commentary at the JPM TMC conference, we now look for better churn and conversion rates in 2020 with the former benefitting from a sharp decline in vehicle related churn,” Petti added.Unsurprisingly, Petti continues to give SIRI his stamp of approval. Along with an Overweight rating, he keeps the price target at $7. Should the target be met, a twelve-month gain of 19% could be in store. (To watch Petti’s track record, click here)Looking at the consensus breakdown, 5 Buys, 3 Holds and 1 Sell have been issued in the last three months. This means that SIRI gets a Moderate Buy consensus rating. Based on the $6.51 average price target, shares could surge 11% in the next year. (See Sirius XM stock analysis on TipRanks)Avid Bioservices Inc. (CDMO)Focused on developing and manufacturing therapies derived from mammalian cell culture, Avid Bioservices wants to help improve the lives of patients. Despite the fact that some healthcare names have experienced major COVID-related disruptions, the pandemic has actually created opportunities for this company.After a recent conference call, Craig-Hallum's Matt Hewitt tells clients that “Avid Bioservices is the top name that we would be buying.” The four-star analyst points out that while there was an equipment issue in the previous quarter, this has been addressed, with the piece of equipment now running properly again.Most important, however, is the increased demand the company is witnessing thanks to COVID-19. “While some pharma/biotech companies have delayed clinical trials, this hasn’t affected any of the products that Avid manufactures, with some customers actually requesting a greater amount of material. Additionally, Avid has increased its inventory of key inputs, helping to minimize supply disruption,” Hewitt explained.It should also be noted that prior to the pandemic’s onset, capacity was tight, so customers may want to take care of this sooner, something that stands to benefit CDMO’s backlog, in Hewitt’s opinion. “There may also be an opportunity for the company to produce treatments or vaccines for the coronavirus, as long as they are antibody-based (not viral vector-based),” the analyst added.On top of this, in May, the company broke the news of its partnership with Aragen Bioscience. The collaboration enables CDMO to offer customers Aragen’s cell line development expertise, while Aragen is able to direct customers to Avid for their process development and manufacturing requirements.Weighing in on the implications, Hewitt stated, “While this announcement may have been ignored by many investors, we view it as a key addition to the company’s platform... As several other CDMOs offer cell line development services (Catalent launched a new technology back in November), we believe this partnership helps fill a key gap in Avid’s service offerings, with cross-sales already beginning to take place. Longer term, we see the potential for more partnerships like this to be signed, particularly for finished dose manufacturing.”According to Hewitt, the growing demand also means that CDMO could expand its manufacturing capacity sooner than he originally expected. It also doesn’t hurt that its CEO search is set to wrap up soon, with the appointment potentially acting as a catalyst for shares.In line with his bullish take, Hewitt reiterated a Buy rating and $10 price target. This target conveys his confidence in CDMO’s ability to climb 40% higher in the next twelve months. (To watch Hewitt’s track record, click here)CDMO has stayed relatively under-the-radar so far, with its Moderate Buy consensus rating breaking down into only 1 Buy. Additionally, the $9 average price target implies 26% upside potential. (See Avid Bioservices stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/02/2020
|
HC Wainwright Reiterates Buy Rating for Avid Bioservices (NASDAQ:CDMO)
- Avid Bioservices (NASDAQ:CDMO)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, TipRanks reports. They currently have a $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 37.20% from the company’s previous close. […]
- 07/02/2020
|
5 Stocks To Watch In Biotech, Space And Manufacturing
- Stocks Analysis by Harry Boxer covering: YRC Worldwide Inc, Amgen Inc, Ballard Power Systems Inc, Tesla Inc. Read Harry Boxer's latest article on Investing.com
- 07/02/2020
|
Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%
- Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 07/01/2020
|
How Avid Bioservices Beat Wall Street Estimates in Q4
- The company still had significant production problems. But it also picked up a lot of new business in Q4.
- 07/01/2020
|
Analysts Are Bullish on These Healthcare Stocks: Avid Bioservices (CDMO), Vericel (VCEL) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avid Bioservices
- 07/01/2020
|
Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options
- Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.
- 07/01/2020
|
Avid Bioservices, Inc. (CDMO) Q4 2020 Earnings Call Transcript
- On today's call, we will have Rick Hancock, Interim President and CEO; Dan Hart, Chief Financial Officer; and Timothy Compton, Chief Commercial Officer. Today, we will be providing an overview of Avid Bioservices' contract development and manufacturing business including updates on corporate activities and financial results for the quarter ended April 30th, 2020.
- 07/01/2020
|
Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options
- Stocks Analysis by Zacks Investment Research covering: Peregrine Pharmaceuticals Inc. Read Zacks Investment Research's latest article on Investing.com
- 07/01/2020
|
Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript
- Avid Bioservices, Inc. (NASDAQ:CDMO) Q4 2020 Earnings Conference Call June 30, 2020, 04:30 PM ET Company Participants Tim Brons - IR Richard Hancock - Interim P
- 06/30/2020
|
AVID BIOSERVICES : Management's Discussion And Analysis Of Financial Condition And Results Of Operations (form 10-K) | MarketScreener
|
Avid Bioservices: Fiscal 4Q Earnings Snapshot | MarketScreener
|
AVID BIOSERVICES, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments | MarketScreener
|
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments
- -- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million -- -- Signed.
- 06/30/2020
|
Avid Bioservices, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Avid Bioservices, Inc. (NASDAQ:CDMO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on June 30, 2020 at 4:30 ...
- 06/30/2020
|
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
ADC Therapeutics SA (...
- 06/30/2020
|
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
- Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development...
- 06/28/2020
|
AVID BIOSERVICES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020 | MarketScreener
|
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020
- TUSTIN, Calif., June 23, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
- 06/23/2020
|
Avid Bioservices Names Nicholas Green as President and Chief Executive Officer | MarketScreener
|
Avid Bioservices Names Nicholas Green as President and Chief Executive Officer
- Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Nicholas Green has been appointed president and chief executive officer, as well as a member of the company’s board of directors, effective July 30, 2020. Mr. Hancock will continue to serve on Avid’s board of directors.
- 06/23/2020
|
Avid Bioservices Inc (NASDAQ:CDMO) Given Consensus Rating of “Buy” by Brokerages
- Shares of Avid Bioservices Inc (NASDAQ:CDMO) have received a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average […]
- 06/22/2020
|
M&T Bank Corp Buys 7,620 Shares of Avid Bioservices Inc (NASDAQ:CDMO)
- M&T Bank Corp increased its stake in Avid Bioservices Inc (NASDAQ:CDMO) by 17.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 51,054 shares of the biopharmaceutical company’s stock after acquiring an additional 7,620 shares during the period. M&T Bank Corp owned about 0.09% of Avid Bioservices […]
- 06/20/2020
|
Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for
- Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 06/18/2020
|
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
- TUSTIN, Calif., June 03, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
- 06/03/2020
|
AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
- AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support
- 05/26/2020
|
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing
- TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing.
- 05/06/2020
|
An Intrinsic Calculation For Avid Bioservices, Inc. (NASDAQ:CDMO) Suggests It's 67% Undervalued
- Today we will run through one way of estimating the intrinsic value of Avid Bioservices, Inc. (NASDAQ:CDMO) by...
- 05/02/2020
|
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
- Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for...
- 04/23/2020
|
Bank of New York Mellon Corp Grows Stock Holdings in Avid Bioservices Inc (NASDAQ:CDMO)
- Bank of New York Mellon Corp increased its position in Avid Bioservices Inc (NASDAQ:CDMO) by 13.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 199,486 shares of the biopharmaceutical company’s stock after acquiring an additional 24,197 shares during the period. Bank […]
- 04/23/2020
|
2 High-Risk, High-Reward Stocks to Add to Your Watch List
- These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.
- 04/22/2020
|
Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia
- Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of two senior directors of business development with responsibility for driving CDMO business growth within North America, Europe and Asia. Jason C. Brady, Ph.D. will serve as senior director of business development for the eastern region of North America, as well as Europe.
- 04/13/2020
|
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 30,625 Avid Bioservices Inc (NASDAQ:CDMO)
- Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Avid Bioservices Inc (NASDAQ:CDMO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 30,625 shares of the biopharmaceutical company’s stock, valued at approximately $235,000. A number of […]
- 04/09/2020
|
Avid Bioservices Receives Five 2020 CMO Leadership Awards
- Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has been named a recipient of five 2020 Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers with the industry’s highest level of service.
- 03/26/2020
|
Analysts Are Bullish on These Healthcare Stocks: Avid Bioservices (CDMO), Agile Therapeutics (AGRX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avid Bioservices (CDMO), Agile Therapeutics (AGRX) and
- 03/20/2020
|
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
- GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with...
- 03/18/2020
|
Insider Buying: The Avid Bioservices, Inc. (NASDAQ:CDMO) Independent Director Just Bought US$104k Worth Of Shares
- Potential Avid Bioservices, Inc. (NASDAQ:CDMO) shareholders may wish to note that the Independent Director, Mark...
- 03/18/2020
|
Mallinckrodt Opioid Deal, And Other News: The Good, Bad And Ugly Of Biopharma
- Vir Biotechnology is up on NIH collaboration in coronavirus. Avid nosedives on missed estimate. Mallinckrodt inches closer to a global opioid deal.
- 03/12/2020
|
Fly Intel: Wall Street's top stories at midday PEP;MNST;KO;DXC;BA;NKE;ADDYY;VIR;CLDR;MTDR;CDMO
- Fly Intel: Wall Street's top stories at midday PEP MNST KO DXC BA NKE ADDYY VIR CLDR MTDR CDMO
- 03/11/2020
|
Fly Intel: Wall Street's top stories for Wednesday PEP;MNST;KO;DXC;BA;ACDVF;ADDYY;TMUS;S;EBAY;VIR;MNK;MTDR;CDMO
- Fly Intel: Wall Street's top stories for Wednesday PEP MNST KO DXC BA ACDVF ADDYY TMUS S EBAY VIR MNK MTDR CDMO
- 03/11/2020
|
Recap: Avid Bioservices Q3 Earnings
- Avid Bioservices (NASDAQ:CDMO) reported Q3 results.Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.• Revenue of $13,585,000 less by 1.42% year over year, which missed the estimate of $15,420,000.Outlook • Q4 revenue expected to be between $55,000,000 and $59,000,000.How To Listen To The Conference Call • Date: Mar 10, 2020• Time: 06:04 AM ETView more earnings on CDMO• Webcast URL: https://edge.media-server.com/mmc/p/vvmbx7zeTechnicals • 52-week high: $8.38• 52-week low: $3.37• Price action over last quarter: Up 12.17%Company Profile Avid Bioservices is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.See more from Benzinga * 146 Biotechnology Stocks Moving In Thursday's Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 03/10/2020
|
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments
- -- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million -- -- Adjusting Fiscal 2020.
- 03/10/2020
|
Avid Bioservices, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Avid Bioservices, Inc. (NASDAQ:CDMO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on March 10, 2020 at 4:30 ...
- 03/10/2020
|
DexCom CEO: Things continue to go very well at the company DXCM
- DexCom CEO: Things continue to go very well at the company DXCM
- 03/10/2020
|
Fly Intel: After Hours Movers HEAR;CLDR;APTO;DXC;CDMO;CLNE;VSLR;KFY;CTRE;HLT
- Fly Intel: After Hours Movers HEAR CLDR APTO DXC CDMO CLNE VSLR KFY CTRE HLT
- 03/10/2020
|
Kosmos CEO buys 300K shares of common stock KOS
- Kosmos CEO buys 300K shares of common stock KOS
- 03/10/2020
|
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
- GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with...
- 03/10/2020
|
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
- TUSTIN, Calif., March 04, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
- 03/04/2020
|
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2020 After Market Close on March 10, 2020
- TUSTIN, Calif., March 03, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
- 03/03/2020
|
When Will Avid Bioservices, Inc. (NASDAQ:CDMO) Become Profitable?
- Avid Bioservices, Inc.'s (NASDAQ:CDMO): Avid Bioservices, Inc., a contract development and manufacturing organization...
- 02/17/2020
|
20 Biopharma Stocks for Huge Upside Potential in 2020
- Here are 20 biotechnology and pharmaceutical stocks that have been given big analyst upside targets for 2020.
- 01/11/2020
|
Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer
- Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Timothy Compton as chief commercial officer. Mr. Compton is an accomplished professional who possesses extensive experience in commercial operations, including sales team management, business development, marketing and corporate development.
- 01/08/2020
|
Can You Imagine How Chuffed Avid Bioservices's (NASDAQ:CDMO) Shareholders Feel About Its 252% Share Price Gain?
- The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- 01/03/2020
|
Should You Buy Avid Bioservices, Inc. (CDMO)?
- We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- 12/16/2019
|
Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates
- Avid Bioservices (CDMO) delivered earnings and revenue surprises of 25.00% and 23.74%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
- 12/09/2019
|
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
- -- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded.
- 12/09/2019
|
Avid Bioservices (CDMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 12/02/2019
|
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
- TUSTIN, Calif., Dec. 02, 2019 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.
- 12/02/2019
|
Estimating The Fair Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)
- Does the November share price for Avid Bioservices, Inc. (NASDAQ:CDMO) reflect what it's really worth? Today, we will...
- 11/19/2019
|
New Strong Sell Stocks for November 7th
- Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- 11/07/2019
|
Avid Bioservices Q3 2019 earnings | AlphaStreet
- Avid Bioservices (CDMO) reported a narrower net loss for the third quarter of 2019, aided by a sharp increase in revenues and lower expenses. The results also topped analysts' expectations. The company's stock jumped about 18% during the extended trading session Monday following the announcement.
- 03/11/2019
|
Avid Bioservices (CDMO) Q2 2019 earnings preview | AlphaStreet
- Avid Bioservices (CDMO), a contract manufacturer in the biotechnology industry, is scheduled to release its second-quarter financial results Monday after the closing bell. Analysts expect the company to report a loss of $0.09 per share, which marks an improvement from last year.
- 12/09/2018
|
